Acknowledgements
If compounds provided by the Molecular Design and Synthesis Center contributed to the findings in your publication, please include the following acknowledgement:
“Compound X was provided by the Vanderbilt Institute of Chemical Biology (VICB), Molecular Design and Synthesis Center (MDSC), Vanderbilt University, Nashville, TN 37232-0412.”
If the design, synthesis, or optimization of the compound involved substantial intellectual input from MDSC, we kindly request that contributing team members be included as co-authors on publications and as co-inventors on patent applications, in accordance with standard scientific authorship and inventorship guidelines, respectively.
Resources
The Molecular Design and Synthesis Core (MDSC) routinely provides investigators and trainees with Letters of Support and/or cost estimates for the synthesis individual tool compounds or sets of analogs as a part of a hit follow-up or hit optimization project. To request a Letter of Support please fill out the project request form. Other proposal support documents can be accessed below under MDSC Resources and Proposal-Support Information.
MDSC Resources and Proposal-Support Information
-
Facilities and Resources FY26
FACILITIES AND RESOURCES (Molecular Design and Synthesis Center, MDSC)
Facilities and Resources -FY2026
RESEARCH LABORATORY SPACE-MDSC
The Vanderbilt Institute of Chemical Biology (VICB) Molecular Design and Synthesis Center (MDSC) is housed on the twelfth floor of Medical Research Building IV. Each staff member is assigned bench space including a 6-foot fume hood, a variety of storage areas and desk space. Ten fully equipped hoods with associated rotary evaporators, stirring hot plates, etc. are assigned to the MDSC. One of the hoods is designated for cGMP (current Good Manufacturing Practice) synthesis with equipment and glassware used specifically for the practice of cGMP syntheses.
OFFICE
Dr. Christov (Scientific Director) and Waterson (VICB, Associate Director for Medicinal Chemistry and Director for Vanderbilt Center for Cancer Drug Discovery) each occupy individual offices. Remaining MDSC staff scientists share an office suite adjacent to open lab space as well as individual lab desks adjacent to assigned hood space.
PERSONNEL
Plamen Christov, Director
Ian Romaine, Ph.D., Drug Discovery Scientist
Benjamin Guttentag, B.S., Research Assistant, senior
Sydnee Elmore, M.S., VICB Lab Manager
Alex G. Waterson, Ph.D., VICB Associate Director for Medicinal Chemistry
Rates 2023-2024 Chemical synthesis projects, including lead optimization (medicinal chemistry), are supported by one or more staff members at a rate of $133.55 per hour, $2,671 per week, $10,684 per month, or $128,208 per year. This rate includes labor plus consumable lab supplies and reagents, while project-specific chemicals and analyses are charged separately. All core members have extensive experience in chemical synthesis and drug discovery.
OVERVIEW OF LEAD OPTIMIZATION PROCESS In addition to providing services focused on the synthesis of single targets, the VICB MDSC has established a process to support extended lead optimization campaigns, often in collaboration with the (VICB) High-Throughput Screening (HTS) core. The molecular design process incorporates principles of modern medicinal chemistry and typically starts from compound(s) that were identified in the initial (HTS) screen(s) or fragment and progressed though hit validation activities. The VICB Associate Director for Medicinal Chemistry (Alex Waterson, Ph.D.) leads hit prioritization and analog design. In conjunction with the core Director (Plamen Christov) and other MDSC staff, synthetic schemes and specific analogs are prioritized based on medicinal chemistry design principles, existing activity data, synthetic accessibility and commercial availability of monomers, as well as patent and literature searches assisted by search engines such as Scifinder.
Scheduled team meetings that include participation from both the “designers” and “synthesizers” are led by Waterson and serve to share and review structure-activity relationship (SAR) data to support subsequent analog design/synthesis cycles aimed at further lead refinement. Concepts of structure-based or property-based drug design are utilized where applicable, and all available assay and physical properties and ADME data are considered to both inform the iterative optimization process and drive progression of individual molecules toward translational program goals.
VANDERBILT COMPOUND COLLECTION The MDSC, established in 2007, is now approaching twenty years of supporting the organic synthesis, chemical probe design-development, and medicinal chemistry needs of researchers across Vanderbilt’s campus as well as external collaborators. Over its lifetime, MDSC has produced a diverse array of small molecules with functional activity. Some of these have been previously reported in the scientific literature, while others are novel, designed and synthesized in collaboration with other research groups. The breadth and diversity of functional small molecules produced by the MDSC since its founding was illustrated in a review article published in 2021 (ACS Chem. Biol., 2021, 16, 787–793). Examples include well-characterized selective small-molecule protein modulators of enzymes, ion channels, GPCRs, kinases, cell death, etc. Many of these compounds are available from milligram to multi-gram quantities, as needed, to support in vitro or in vivo studies. Indeed, the MDSC maintains a catalog of over 500 compounds available on demand to Vanderbilt and external investigators. Many of these compounds have been pharmacologically characterized, and many may have as yet unknown activities. Selected examples of available small molecule probes with potential utility in biochemical and biological studies is provided below. The MDSC also has the ability, in collaboration with VUII radiochemistry group, to provide access to 18F-labeled chemical probes for imaging studies.

-
Data Management Plan
Compound Characterization and Sample Storage Compound characterization data will be stored on computer hard drives and backed up on a university hard drive including LC-MS and NMR data. Specifically, NMR spectra are written and stored in Bruker’s documented data format. This NMR data can be viewed and analyzed by Bruker’s widely available TOPSPIN software and by software published by myriad 3rd party vendors. NMR data is written to the hard disk of the spectrometer computer at the time of collection and mirrored to a second physical location maintained by the Vanderbilt Distributed Online Research Storage project (dors). Dors operates a high-performance storage facility from the Hill Center on the Vanderbilt campus with associated backup policies, ensuring that spectral data collected can be retained by the Small Molecule NMR Facility indefinitely. NMR Data stored on dors is accessible to users with a VUNetID and password from any computer on the VU network. Users are restricted to accessing data in their own directory via this system. Integration of the proposed instrument into this system is expected to be trivial, as this system is redundant and scalable by design and has been in place for many years.
Samples of final compounds and select intermediates along synthetic routes are stored within the Molecular Design and Synthesis Center in temperature-controlled refrigeration units. In some cases, samples will be maintained with the High-Throughput facility compound storage unit.
-
Authentication Chemicals
Authentication PLAN
Chemical Resources
Synthetic procedures and product analysis data are documented using electronic lab notebooks, Small molecules produced by chemical synthesis are subjected to LC-MS, 1H/13C/DEPT NMR analysis, HRMS, as appropriate. Synthetic protocols are documented with characterization data, and final products are registered by batch within the VU compound registration system.
VU and VUMC faculty may consider applying for internal funding to cover project costs. The MDSC can assist in such applications by providing detailed cost estimates (to start process either submit a Project Request and/or contact core director).
Preferred Contract Research Organizations-In addition to internal support, MDSC maintains collaborations with several external CROs to extend capabilities in areas.
-
IQVIA Labs
Provides in vitro ADME and physicochemical properties analysis.
Please contact MDSC core director for assistance in sample submission.
-
Lotus Separations
Provides chiral separation of enantiomers.
-
Reaction Biology
Provides multiple assays and resources to support pre-clinical profiling.
-
For protein production
We recommend Pharmaron, or Viva Biotech.
Publications
-
2026
Katherine Clowes Moster*, Ana Chang-Gonzalez, Ian Romaine, Katherine Stefanski, Mason Wilkinson, Joshua Bauer, Thomas Hasaka, Emily Days, Kathryn Butcher, Gary Sulikowski, Alex Waterson, Jens Meiler, Kaitlyn Ledwitch, Charles Sanders; High throughput screening identifies a trafficking corrector for long-QT syndrome associated KCNQ1 variants. JCI Insight. DOI: 1172/jci.insight.201297
Alex Waterson;, Anish Vadukoot;, Somnath Jana;, Jianwen Cui; Kelvin Luong; Tyson Rietz; Ezequiel Alejandro Madrigal-Carrillo, Brian Lehmann; John Sensintaffar; Bin Zhao; Kangsa Amporndanai; Zoe A. Petros; William Scaggs; Simon Chacon, Selena; Vekariya, Rakesh; Kwangho Kim; Manikandan Thangaraj; Plamen Christov; Taylor South; Jiqing Sai; Anusha Thiruvaipati; Charles. Identification of KLHL12 ligands using fragment-based methods. J. Med. Chem. 2026, 69, 7, 7709–7731 acs.jmedchem.5c02931
Alexander P. Ligocki; Alexander G. Sorets; Adam M. Abdulrahman; Nora Francini; Joshua C. Park; Ju Ha Lee; William T. Ford; Sarah M. Lyons; Emma L. Fritsch; Zachary E. Lamantia; Plamen P. Christov; Elika Eshraghi Tehrani; Craig L. Duvall; Ethan S Lippmann. Evaluating the effects of aging on biodistribution and gene silencing activity of lipid-siRNA conjugates delivered into cerebrospinal fluid. Molecular Therapy; doi: 10.64898/2025.12.17.693452.
Nina Gubina; Plamen Christov; Lawrence Marnett, Essigmann, John; Bogdan Fedeles. The oxidative DNA lesion 6-Oxo-M1dG is a potent replication block, inducing deletions and base substitution mutations in vivo. Chem. Res. Toxicol, submitted.
Spearing, Paul; Satpute , Vaishali ; Romaine, Ian; Jayakodiarachchi, Navoda; Guttentag, Benjamin W.; Jana, Somnath; Kim, Kwangho; Denton, Jerod S.; Lindsley, Craig; Waterson, Alex; Optimization of pyrazole-based activators of Kv3.1. ACS Medicinal Chemistry Letters, in print
Vadukoot, Anish; Petros, Zoe A.; Thangaraj, Manikandan; Madrigal-Carrillo, Ezequiel Alejandro; Cui, Jianwen; Jana, Somnath; Kim, Kwangho; Christov, Plamen; Guttentag, Benjamin W.; Luong, Kelvin; Sensintaffar, John; Scaggs, William; South, Taylor; Apakama, Chideraa; Wilson, Genesis; Van Meveren, Mayme; Sai, Jiqing; Amporndanai, Kangsa; Thiruvaipati, Anusha; Schmidt, Charles R.; Eells, Rebecca; Phan, Jason; Waterson, Alex; Fesik, Stephen; Discovery of a naphthyridine series of KLHL12-based PROTACs. Journal of Medicinal Chemistry, submitted.
-
2025
Martinez LA, Imami A, de Jong E, Romaine IM, Zwiebel LJ. Binary mixtures of Vanderbilt University allosteric agonist thermolysis components act as volatile spatial repellents for malaria vector mosquitoes. Pest Manag Sci. 2025 Jan;81(1):185-195. doi:10.1002/ps.8421
Shealy NG, Baltagulov M, de Brito C, McGovern A, Castro P, Schrimpe-Rutledge AC, Malekshahi C, Condreanu SG, Sherrod SD, Jana S, Jones K, Ribeiro TM, McLean JA, Beiting DP, Byndloss MX. Short-term alterations in dietary amino acids override host genetic susceptibility and reveal mechanisms of Salmonella Typhimurium small intestine colonization. bioRxiv [Preprint]. 2025 Mar 25:2025.03.25.645332. doi: 10.1101/2025.03.25.645332Kim M, Kim K, Lee J, Barny LA, Scaggs TD, Romaine IM, Jeon K, Codreanu SG, Sherrod SD, McLean JA, Naren AP, Sulikowski GA, Plate L. Photoaffinity Ligand of Cystic Fibrosis Corrector VX-445 Identifies SCCPDH as an Off-Target. ACS Chem Biol. 2025 Jul 18;20(7):1560-1573. doi: 10.1021/acschembio.5c00157
. Epub 2025 Jun 20.Cameron C, Clark RM, Metts AM, Jiang RM, Scaggs TD, Kim K, Sulikowski GA, Plate L. Time-Resolved Analysis of Protein-Protein Ensembles Using a Destabilizing Domain to Map Dynamic Interactions of SARS-CoV-2 nsp15. ACS Chem Biol. 2025 Sep 19;20(9):2229-2242. doi: 10.1021/acschembio.5c00377. Epub 2025 Sep 1.
Tarr JC, Jeon K, Veerasamy N, Aichinger M, Salovich JM, Zhao B, Sensintaffar JL, Arnhof H, Wunberg T, Sgubin D, Arnold A, Vekariya RH, Christov PP, Kim K, Fuchs JE, Karier P, Betzemeier B, Van Meveren M, Miriyala N, Olejniczak ET, Engelhardt H, Lee T, McConnell D, Fesik SW. Discovery of Macrocyclic Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors that Demonstrate Potent Cellular Efficacy and In Vivo Activity in a Mouse Solid Tumor Xenograft Model. J Med Chem. 2025 Sep 11;68(17):18553-18578. doi: 10.1021/acs.jmedchem.5c01376. Epub 2025 Aug 27
-
2024
Carvajal-Garcia J, Bracey H, Johnson AE, Hernandez Viera AJ, Egli M, Simsek EN, Jaremba EA, Kim K, Merrikh H. A small molecule that inhibits the evolution of antibiotic resistance. NAR Mol Med. 2024 Jan 23;1(1):ugae001. doi: 10.1093/narmme/ugae001.
Pastora LE, Namburu NS, Arora K, Christov PP, Wilson JT. STING-Pathway Inhibiting Nanoparticles (SPINs) as a Platform for Treatment of Inflammatory Diseases. ACS Appl Bio Mater. 2024 Aug 19;7(8):4867-4878. doi: 10.1021/acsabm.3c01305. Epub 2024 Apr 2.
Baljon JJ, Kwiatkowski AJ, Pagendarm HM, Stone PT, Kumar A, Bharti V, Schulman JA, Becker KW, Roth EW, Christov PP, Joyce S, Wilson JT. A Cancer Nanovaccine for Co-Delivery of Peptide Neoantigens and Optimized Combinations of STING and TLR4 Agonists. ACS Nano. 2024 Mar 5;18(9):6845-6862. doi: 10.1021/acsnano.3c04471. Epub 2024 Feb 22.
Hawes EM, Rahim M, Haratipour Z, Orun AR, O'Rourke ML, Oeser JK, Kim K, Claxton DP, Blind RD, Young JD, O'Brien RM. Biochemical and metabolic characterization of a G6PC2 inhibitor. Biochimie. 2024 Jul;222:109-122. doi: 10.1016/j.biochi.2024.02.012. Epub 2024 Mar 1.Won Y, Jang B, Lee SH, Reyzer ML, Presentation KS, Kim H, Caldwell B, Zhang C, Lee HS, Lee C, Trinh VQ, Tan MCB, Kim K, Caprioli RM, Choi E. Oncogenic Fatty Acid Metabolism Rewires Energy Supply Chain in Gastric Carcinogenesis. Gastroenterology. 2024 May;166(5):772-786.e14. doi: 10.1053/j.gastro.2024.01.027. Epub 2024 Jan 24.
-
2023
Fu Y, Christov PP, Kingsley PJ, Richie-Jannetta RM, Marnett LJ, Stone MP. Base-Displaced Intercalated Structure of the 3-(2-Deoxy-β-D-erythropentofuranosyl)-pyrimido[1,2-f]purine-6,10(3H,5H)-dione (6-oxo-M1dG) Lesion in DNA. Chem Res Toxicol. 2023 Dec 18;36(12):1947-1960. doi: 10.1021/acs.chemrestox.3c00226. Epub 2023 Nov 21.
Wang-Bishop L, Kimmel BR, Ngwa VM, Madden MZ, Baljon JJ, Florian DC, Hanna A, Pastora LE, Sheehy TL, Kwiatkowski AJ, Wehbe M, Wen X, Becker KW, Garland KM, Schulman JA, Shae D, Edwards D, Wolf MM, Delapp R, Christov PP, Beckermann KE, Balko JM, Rathmell WK, Rathmell JC, Chen J, Wilson JT. STING-activating nanoparticles normalize the vascular-immune interface to potentiate cancer immunotherapy. Sci Immunol. 2023 May 12;8(83):eadd1153. doi:10.1126/sciimmunol.add1153. Epub 2023 May 5.
Siricilla S, Hansen CJ, Rogers JH, De D, Simpson CL, Waterson AG, Sulikowski GA, Crockett SL, Boatwright N, Reese J, Paria BC, Newton J, Herington JL. Arrest of mouse preterm labor until term delivery by combination therapy with atosiban and mundulone, a natural product with tocolytic efficacy. Pharmacol Res. 2023 Sep;195:106876. doi:10.1016/j.phrs.2023.106876. Epub 2023 Aug 1Zarrow JE, Alli-Oluwafuyi AM, Youwakim CM, Kim K, Jenkins AN, Suero IC, Jones MR, Mashhadi Z, Mackie K, Waterson AG, Doran AC, Sulikowski GA, Davies SS. Small Molecule Activation of NAPE-PLD Enhances Efferocytosis by Macrophages. ACS Chem Biol. 2023 Aug 18;18(8):1891-1904. doi: 10.1021/acschembio.3c00401. Epub 2023 Aug 2.
-
2022
Prael Iii FJ, Kim K, Du Y, Spitznagel BD, Sulikowski GA, Delpire E, Weaver CD. Discovery of Small Molecule KCC2 Potentiators Which Attenuate In Vitro Seizure-Like Activity in Cultured Neurons. Front Cell Dev Biol. 2022 Jun 24;10:912812. doi: 10.3389/fcell.2022.912812.
Kelly KP, Borsetti H, Wenzler ME, Ustione A, Kim K, Christov PP, Ramirez B, Bauer JA, Piston DW, Johnson CH, Sulikowski GA. Screen for Small-Molecule Modulators of Circadian Rhythms Reveals Phenazine as a Redox-State Modifying Clockwork Tuner. ACS Chem Biol. 2022 Jul 15;17(7):1658-1664. doi: 10.1021/acschembio.2c00240. Epub 2022 Jun 9.Xu J, Sun X, Kim K, Brand RM, Hartman D, Ma H, Brand RE, Bai M, Liu Y. Ultrastructural visualization of chromatin in cancer pathogenesis using a simple small-molecule fluorescent probe. Sci Adv. 2022 Mar 4;8(9):eabm8293. doi: 10.1126/sciadv.abm8293. Epub 2022 Mar 4.
Çakır I, Hadley CK, Pan PL, Bagchi RA, Ghamari-Langroudi M, Porter DT, Wang Q, Litt MJ, Jana S, Hagen S, Lee P, White A, Lin JD, McKinsey TA, Cone RD. Histone deacetylase 6 inhibition restores leptin sensitivity and reduces obesity. Nat Metab. 2022 Jan;4(1):44-59. doi: 10.1038/s42255-021-00515-3. Epub 2022 Jan 17.
-
2021
Zarrow JE, Tian J, Dutter B, Kim K, Doran AC, Sulikowski GA, Davies SS. Selective measurement of NAPE-PLD activity via a PLA1/2-resistant fluorogenic N-acyl-phosphatidylethanolamine analog. J Lipid Res. 2022 Jan;63(1):100156. doi: 10.1016/j.jlr.2021.100156. Epub 2021 Nov 26.
Christov PP, Richie-Jannetta R, Kingsley PJ, Vemulapalli A, Kim K, Sulikowski GA, Rizzo CJ, Ketkar A, Eoff RL, Rouzer CA, Marnett LJ. Site-Specific Synthesis of Oligonucleotides Containing 6-Oxo-M1dG, the Genomic Metabolite of M1dG, and Liquid Chromatography-Tandem Mass Spectrometry Analysis of Its In Vitro Bypass by Human Polymerase ι. Chem Res Toxicol. 2021 Dec 20;34(12):2567-2578. doi: 10.1021/acs.chemrestox.1c00334. Epub 2021 Dec 3.Kozlyuk N, Gilston BA, Salay LE, Gogliotti RD, Christov PP, Kim K, Ovee M, Waterson AG, Chazin WJ. A fragment-based approach to discovery of Receptor for Advanced Glycation End products inhibitors. Proteins. 2021 Nov;89(11):1399-1412. doi: 10.1002/prot.26162. Epub 2021 Jul 2.
Christov PP, Kim K, Jana S, Romaine IM, Rai G, Mott BT, Allweil AA, Lamers A, Brimacombe KR, Urban DJ, Lee TD, Hu X, Lukacs CM, Davies DR, Jadhav A, Hall MD, Green N, Moore WJ, Stott GM, Flint AJ, Maloney DJ, Sulikowski GA, Waterson AG. Optimization of ether and aniline based inhibitors of lactate dehydrogenase. Bioorg Med Chem Lett. 2021 Jun 1;41:127974. doi: 10.1016/j.bmcl.2021.127974. Epub 2021 Mar 24.
Kim K, Christov PP, Romaine I, Tian J, Jana S, Lamers AP, Dutter BF, Scaggs T, Jeon K, Guttentag B, Weaver CD, Lindsley CW, Waterson AG, Sulikowski GA. Ten-Year Retrospective of the Vanderbilt Institute of Chemical Biology Chemical Synthesis Core. ACS Chem Biol. 2021 May 21;16(5):787-793. doi: 10.1021/acschembio.0c00818. Epub 2021 Apr 20.Wehbe M, Wang-Bishop L, Becker KW, Shae D, Baljon JJ, He X, Christov P, Boyd KL, Balko JM, Wilson JT. Nanoparticle delivery improves the pharmacokinetic properties of cyclic dinucleotide STING agonists to open a therapeutic window for intravenous administration. J Control Release. 2021 Feb 10;330:1118-1129. doi: 10.1016/j.jconrel.2020.11.017. Epub 2020 Nov 12.
Nguyen DC, Shae D, Pagendarm HM, Becker KW, Wehbe M, Kilchrist KV, Pastora LE, Palmer CR, Seber P, Christov PP, Duvall CL, Wilson JT. Amphiphilic Polyelectrolyte Graft Copolymers Enhance the Activity of Cyclic Dinucleotide STING Agonists. Adv Healthc Mater. 2021 Jan;10(2):e2001056. doi: 10.1002/adhm.202001056. Epub 2020 Nov 23. -
2020
Rai G, Urban DJ, Mott BT, Hu X, Yang SM, Benavides GA, Johnson MS, Squadrito GL, Brimacombe KR, Lee TD, Cheff DM, Zhu H, Henderson MJ, Pohida K, Sulikowski GA, Dranow DM, Kabir M, Shah P, Padilha E, Tao D, Fang Y, Christov PP, Kim K, Jana S, Muttil P, Anderson T, Kunda NK, Hathaway HJ, Kusewitt DF, Oshima N, Cherukuri M, Davies DR, Norenberg JP, Sklar LA, Moore WJ, Dang CV, Stott GM, Neckers L, Flint AJ, Darley-Usmar VM, Simeonov A, Waterson AG, Jadhav A, Hall MD, Maloney DJ. Pyrazole-Based Lactate Dehydrogenase Inhibitors with Optimized Cell Activity and Pharmacokinetic Properties. J Med Chem. 2020 Oct 8;63(19):10984-11011. doi: 10.1021/acs.jmedchem.0c00916. Epub 2020 Sep 27.
Juttukonda LJ, Beavers WN, Unsihuay D, Kim K, Pishchany G, Horning KJ, Weiss A, Al-Tameemi H, Boyd JM, Sulikowski GA, Bowman AB, Skaar EP. A Small-Molecule Modulator of Metal Homeostasis in Gram-Positive Pathogens. mBio. 2020 Oct 27;11(5):e02555-20. doi: 10.1128/mBio.02555-20.Kimbrough JR, Jana S, Kim K, Allweil A, Oates JA, Milne GL, Sulikowski GA. Synthesis of tetranor-PGE1: a urinary metabolite of prostaglandins E1 and E2. Tetrahedron Lett. 2020 May 28;61(22):151922. doi: 10.1016/j.tetlet.2020.151922. Epub 2020 Apr 10.
Horning KJ, Joshi P, Nitin R, Balachandran RC, Yanko FM, Kim K, Christov P, Aschner M, Sulikowski GA, Weaver CD, Bowman AB. Identification of a selective manganese ionophore that enables nonlethal quantification of cellular manganese. J Biol Chem. 2020 Mar 20;295(12):3875-3890. doi: 10.1074/jbc.RA119.009781. Epub 2020 Feb 11
Wang-Bishop L, Wehbe M, Shae D, James J, Hacker BC, Garland K, Chistov PP, Rafat M, Balko JM, Wilson JT. Potent STING activation stimulates immunogenic cell death to enhance antitumor immunity in neuroblastoma. J Immunother Cancer. 2020 Mar;8(1):e000282. doi: 10.1136/jitc-2019-000282. -
2019
Minko IG, Christov PP, Li L, Stone MP, McCullough AK, Lloyd RS. Processing of N5-substituted formamidopyrimidine DNA adducts by DNA glycosylases NEIL1 and NEIL3. DNA Repair (Amst). 2019 Jan;73:49-54. doi: 10.1016/j.dnarep.2018.11.001. Epub 2018 Nov 5.
Perry E, Mills JJ, Zhao B, Wang F, Sun Q, Christov PP, Tarr JC, Rietz TA, Olejniczak ET, Lee T, Fesik S. Fragment-based screening of programmed death ligand 1 (PD-L1). Bioorg Med Chem Lett. 2019 Mar 15;29(6):786-790. doi: 10.1016/j.bmcl.2019.01.028. Epub 2019 Jan 24.Lee T, Christov PP, Shaw S, Tarr JC, Zhao B, Veerasamy N, Jeon KO, Mills JJ, Bian Z, Sensintaffar JL, Arnold AL, Fogarty SA, Perry E, Ramsey HE, Cook RS, Hollingshead M, Davis Millin M, Lee KM, Koss B, Budhraja A, Opferman JT, Kim K, Arteaga CL, Moore WJ, Olejniczak ET, Savona MR, Fesik SW. Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors That Demonstrate in Vivo Activity in Mouse Xenograft Models of Human Cancer. J Med Chem. 2019 Apr 25;62(8):3971-3988. doi: 10.1021/acs.jmedchem.8b01991. Epub 2019 Apr 16.
Shae D, Becker KW, Christov P, Yun DS, Lytton-Jean AKR, Sevimli S, Ascano M, Kelley M, Johnson DB, Balko JM, Wilson JT. Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy. Nat Nanotechnol. 2019 Mar;14(3):269-278. doi: 10.1038/s41565-018-0342-5. Epub 2019 Jan 21.
Dumas ME, Chen GY, Kendrick ND, Xu G, Larsen SD, Jana S, Waterson AG, Bauer JA, Hancock W, Sulikowski GA, Ohi R. Dual inhibition of Kif15 by oxindole and quinazolinedione chemical probes. Bioorg Med Chem Lett. 2019 Jan 15;29(2):148-154. doi: 10.1016/j.bmcl.2018.12.008. Epub 2018 Dec 4.
-
2018
Davis RW, Allweil A, Tian J, Brash AR, Sulikowski GA. Stereocontrolled synthesis of four isomeric linoleate triols of relevance to skin barrier formation and function. Tetrahedron Lett. 2018 Dec 26;59(52):4571-4573. doi: 10.1016/j.tetlet.2018.11.033. Epub 2018 Nov 10.
Yamanashi H, Boeglin WE, Morisseau C, Davis RW, Sulikowski GA, Hammock BD, Brash AR. Catalytic activities of mammalian epoxide hydrolases with cis and trans fatty acid epoxides relevant to skin barrier function. J Lipid Res. 2018 Apr;59(4):684-695. doi: 10.1194/jlr.M082701. Epub 2018 Feb 19.
Abney KK, Ramos-Hunter SJ, Romaine IM, Goodwin JS, Sulikowski GA, Weaver CD. Selective Activation of N,N'-Diacyl Rhodamine Pro-fluorophores Paired with Releasing Enzyme, Porcine Liver Esterase (PLE). Chemistry. 2018 Jun 26;24(36):8985-8988. doi: 10.1002/chem.201801409. Epub 2018 May 25.
Boer RE, Giménez-Bastida JA, Boutaud O, Jana S, Schneider C, Sulikowski GA. Total Synthesis and Biological Activity of the Arachidonic Acid Metabolite Hemiketal E2. Org Lett. 2018 Jul 6;20(13):4020-4022. doi: 10.1021/acs.orglett.8b01578. Epub 2018 Jun 19.
Dutter BF, Ender A, Sulikowski GA, Weaver CD. Rhodol-based thallium sensors for cellular imaging of potassium channel activity. Org Biomol Chem. 2018 Aug 8;16(31):5575-5579. doi: 10.1039/c8ob01098f.
-
2017
Surdel MC, Horvath DJ Jr, Lojek LJ, Fullen AR, Simpson J, Dutter BF, Salleng KJ, Ford JB, Jenkins JL, Nagarajan R, Teixeira PL, Albertolle M, Georgiev IS, Jansen ED, Sulikowski GA, Lacy DB, Dailey HA, Skaar EP. Antibacterial photosensitization through activation of coproporphyrinogen oxidase. Proc Natl Acad Sci U S A. 2017 Aug 8;114(32):E6652-E6659. doi: 10.1073/pnas.1700469114. Epub 2017 Jul 24.
Lepesheva G, Christov P, Sulikowski GA, Kim K. A convergent, scalable and stereoselective synthesis of azole CYP51 inhibitors. Tetrahedron Lett. 2017 Nov 8;58(45):4248-4250. doi: 10.1016/j.tetlet.2017.09.070. Epub 2017 Sep 25.
-
2016
Choby JE, Mike LA, Mashruwala AA, Dutter BF, Dunman PM, Sulikowski GA, Boyd JM, Skaar EP. A Small-Molecule Inhibitor of Iron-Sulfur Cluster Assembly Uncovers a Link between Virulence Regulation and Metabolism in Staphylococcus aureus. Cell Chem Biol. 2016 Nov 17;23(11):1351-1361. doi: 10.1016/j.chembiol.2016.09.012. Epub 2016 Oct 20.
Surdel MC, Dutter BF, Sulikowski GA, Skaar EP. Bacterial Nitric Oxide Synthase Is Required for the Staphylococcus aureus Response to Heme Stress. ACS Infect Dis. 2016 Aug 12;2(8):572-8. doi: 10.1021/acsinfecdis.6b00081. Epub 2016 Jul 7.
Chong KM, Leelatian N, Deguire SM, Brockman AA, Earl D, Ihrie RA, Irish JM, Bachmann BO, Sulikowski GA. The use of fluorescently-tagged apoptolidins in cellular uptake and response studies. J Antibiot (Tokyo). 2016 Apr;69(4):327-30. doi: 10.1038/ja.2016.22. Epub 2016 Mar 9.
Dutter BF, Mike LA, Reid PR, Chong KM, Ramos-Hunter SJ, Skaar EP, Sulikowski GA. Decoupling Activation of Heme Biosynthesis from Anaerobic Toxicity in a Molecule Active in Staphylococcus aureus. ACS Chem Biol. 2016 May 20;11(5):1354-61. doi: 10.1021/acschembio.5b00934. Epub 2016 Mar 4.
-
2015
Senter TJ, O'Reilly MC, Chong KM, Sulikowski GA, Lindsley CW. A general, enantioselective synthesis of N-alkyl terminal aziridines and C2-functionalized azetidines via organocatalysis. Tetrahedron Lett. 2015 Mar 4;56(10):1276-1279. doi: 10.1016/j.tetlet.2015.01.140.
Romaine IM, Sulikowski GA. Studies on a biomimetic oxidative dimerization approach to the hibarimicins. Tetrahedron Lett. 2015 Jun 3;56(23):3617-3619. doi: 10.1016/j.tetlet.2015.01.127.
Williams CH, Hempel JE, Hao J, Frist AY, Williams MM, Fleming JT, Sulikowski GA, Cooper MK, Chiang C, Hong CC. An in vivo chemical genetic screen identifies phosphodiesterase 4 as a pharmacological target for hedgehog signaling inhibition. Cell Rep. 2015 Apr 7;11(1):43-50. doi: 10.1016/j.celrep.2015.03.001. Epub 2015 Mar 26.
-
2014
Evans SM, Kim K, Moore CE, Uddin MI, Capozzi ME, Craft JR, Sulikowski GA, Jayagopal A. Molecular probes for imaging of hypoxia in the retina. Bioconjug Chem. 2014 Nov 19;25(11):2030-7. doi: 10.1021/bc500400z. Epub 2014 Oct 9.
Romaine IM, Taylor RW, Saidu SP, Kim K, Sulikowski GA, Zwiebel LJ, Waterson AG. Narrow SAR in odorant sensing Orco receptor agonists. Bioorg Med Chem Lett. 2014 Jun 15;24(12):2613-6. doi: 10.1016/j.bmcl.2014.04.081. Epub 2014 Apr 29.
-
2013
Thompson MK, Keithly ME, Harp J, Cook PD, Jagessar KL, Sulikowski GA, Armstrong RN. Structural and chemical aspects of resistance to the antibiotic fosfomycin conferred by FosB from Bacillus cereus. Biochemistry. 2013 Oct 15;52(41):7350-62. doi: 10.1021/bi4009648. Epub 2013 Sep 30.
Wen W, Wu W, Romaine IM, Kaufmann K, Du Y, Sulikowski GA, Weaver CD, Lindsley CW. Discovery of 'molecular switches' within a GIRK activator scaffold that afford selective GIRK inhibitors. Bioorg Med Chem Lett. 2013 Aug 15;23(16):4562-6. doi: 10.1016/j.bmcl.2013.06.023. Epub 2013 Jun 20.
Kaufmann K, Romaine I, Days E, Pascual C, Malik A, Yang L, Zou B, Du Y, Sliwoski G, Morrison RD, Denton J, Niswender CM, Daniels JS, Sulikowski GA, Xie XS, Lindsley CW, Weaver CD. ML297 (VU0456810), the first potent and selective activator of the GIRK potassium channel, displays antiepileptic properties in mice. ACS Chem Neurosci. 2013 Sep 18;4(9):1278-86. doi: 10.1021/cn400062a. Epub 2013 Jun 13. -
2012
Hargrove TY, Kim K, de Nazaré Correia Soeiro M, da Silva CF, Batista DD, Batista MM, Yazlovitskaya EM, Waterman MR, Sulikowski GA, Lepesheva GI. CYP51 structures and structure-based development of novel, pathogen-specific inhibitory scaffolds. Int J Parasitol Drugs Drug Resist. 2012 Dec;2:178-186. doi: 10.1016/j.ijpddr.2012.06.001. Epub 2012 Jun 30.
Liedtke AJ, Kim K, Stec DF, Sulikowski GA, Marnett LJ. Straightforward protocol for the efficient synthesis of varied N(1)-acylated (aza)indole 2-/3-alkanoic acids and esters: optimization and scale-up. Tetrahedron. 2012 Dec 2;68(48):10049-10058. doi: 10.1016/j.tet.2012.08.044.
Lamers AP, Keithly ME, Kim K, Cook PD, Stec DF, Hines KM, Sulikowski GA, Armstrong RN. Synthesis of bacillithiol and the catalytic selectivity of FosB-type fosfomycin resistance proteins. Org Lett. 2012 Oct 19;14(20):5207-9. doi: 10.1021/ol302327t. Epub 2012 Oct 3.
Taylor RW, Romaine IM, Liu C, Murthi P, Jones PL, Waterson AG, Sulikowski GA, Zwiebel LJ. Structure-activity relationship of a broad-spectrum insect odorant receptor agonist. ACS Chem Biol. 2012 Oct 19;7(10):1647-52. doi: 10.1021/cb300331z. Epub 2012 Aug 27.
Jones PL, Pask GM, Romaine IM, Taylor RW, Reid PR, Waterson AG, Sulikowski GA, Zwiebel LJ. Allosteric antagonism of insect odorant receptor ion channels. PLoS One. 2012;7(1):e30304. doi: 10.1371/journal.pone.0030304. Epub 2012 Jan 17.Melancon BJ, Lamers AP, Bridges TM, Sulikowski GA, Utley TJ, Sheffler DJ, Noetzel MJ, Morrison RD, Daniels JS, Niswender CM, Jones CK, Conn PJ, Lindsley CW, Wood MR. Development of a more highly selective M(1) antagonist from the continued optimization of the MLPCN Probe ML012. Bioorg Med Chem Lett. 2012 Jan 15;22(2):1044-8. doi: 10.1016/j.bmcl.2011.11.110. Epub 2011 Dec 6.